Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Two-Stage, Open-Label, Randomized, Crossover Study Evaluating the Pharmacokinetics of Single Doses of Two Investigational Rifaximin Soluble Solid Dispersion Formulations (Immediate Release and Sustained Extended Release) in Healthy Volunteers

Trial Profile

A Two-Stage, Open-Label, Randomized, Crossover Study Evaluating the Pharmacokinetics of Single Doses of Two Investigational Rifaximin Soluble Solid Dispersion Formulations (Immediate Release and Sustained Extended Release) in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 16 May 2018

At a glance

  • Drugs Rifaximin (Primary) ; Rifaximin (Primary)
  • Indications Hepatic encephalopathy; Liver disorders
  • Focus Pharmacokinetics
  • Most Recent Events

    • 16 May 2018 New trial record
    • 14 Apr 2018 Results presented at The International Liver Congress 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top